Your browser doesn't support javascript.
A case series report on successful management of patients with COVID-19-associated lymphopenia and potential application of PG2.
Wang, Wei-Yao; Lee, Yuan-Ti; Wang, Yao-Tung; Chen, Ji-Zhen; Lee, Su-Yin; Tsao, Shih-Ming.
  • Wang WY; Division of Infectious Disease, School of Medicine, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan.
  • Lee YT; Division of Infectious Disease, School of Medicine, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan.
  • Wang YT; Division of Chest Medicine, School of Medicine, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan.
  • Chen JZ; Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Lee SY; Infection Control Center, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Tsao SM; Division of Chest Medicine, School of Medicine, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan.
Front Med (Lausanne) ; 9: 1009557, 2022.
Article in English | MEDLINE | ID: covidwho-2142058
ABSTRACT

Background:

Lymphopenia and the resultant high neutrophil-to-lymphocyte ratio (NLR) are hallmark signs of severe COVID-19, and effective treatment remains unavailable. We retrospectively reviewed the outcomes of COVID-19 in a cohort of 26 patients admitted to Chung Shan Medical University Hospital (Taichung City, Taiwan). Twenty-five of the 26 patients recovered, including 9 patients with mild/moderate illness and 16 patients with severe/critical illness recovered. One patient died after refusing treatment. Case presentation We report the cases of four patients with high NLRs and marked lymphopenia, despite receiving standard care. A novel injectable botanical drug, PG2, containing Astragalus polysaccharides, was administered to them as an immune modulator. The decrease in the NLR in these four patients was faster than that of other patients in the cohort (0.80 vs. 0.34 per day).

Conclusion:

All patients recovered from severe COVID-19 showed decreased NLR and normalized lymphocyte counts before discharge. Administration of PG2 may be of benefit to patients with moderate to severe COVID-19 and lymphopenia.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Cohort study / Observational study / Prognostic study Language: English Journal: Front Med (Lausanne) Year: 2022 Document Type: Article Affiliation country: Fmed.2022.1009557

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Cohort study / Observational study / Prognostic study Language: English Journal: Front Med (Lausanne) Year: 2022 Document Type: Article Affiliation country: Fmed.2022.1009557